NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Diagnostics & Research · USD

IQVIA Holdings Inc. (IQV) Stock Analysis

IQVIA Holdings Inc. (IQV) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

IQV

$267.77

−$3.85 (−1.42%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IQV with… →

IQV Key Statistics

As of Sep 4, 2026
Trading
Open
$268.48
Previous Close
$271.62
Day's Range
262.60–271.80
52-Week Range
154.50–271.80
Volume
1.20M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
Market Cap
$44.07B
P/E Ratio
33.77
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
18.52
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.94
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.60
EPS (ttm)Profit attributable to each share over the last twelve months.
7.93
Financials (FY)
Revenue (FY)
$16.31B+5.87%
Net Income (FY)
$1.36B−0.95%
Profit marginThe share of revenue left as profit after all costs and taxes.
8.10%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
164.60M
1-Year Return
+45.46%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.45M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IQV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+18.79%
2025+14.71%
2024−15.07%
2023+12.93%
2022−27.38%
2021+57.47%
2020+15.96%
2019+33.00%
2018+18.66%
2017+28.73%
2016 (partial year)−0.67%

As of September 4, 2026.

IQV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.31B$1.36B8.3%
2024$15.41B$1.37B8.9%
2023$14.98B$1.36B9.1%
2022$14.41B$1.09B7.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.31B$5.43B$2.29B$1.36B8.3%
2024$15.41B$5.38B$2.27B$1.37B8.9%
2023$14.98B$5.24B$2.06B$1.36B9.1%
2022$14.41B$5.03B$1.83B$1.09B7.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IQV Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricIQVDiagnostics & Research medianvs median
P/E33.7733.082% above
P/S ratio2.604.9948% below
Profit margin8.10%0.00%8.1 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

IQVIA Holdings Inc. (IQV) carries a market capitalisation of $44.07B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 94,000.

IQV last closed at $267.77 on September 4, 2026. That is −$3.85 (−1.42%) against the previous close. The 52-week range on file runs from $154.50 to $271.80. The latest close sits 73.31% above that 52-week low.

Financial Health

In fiscal 2025, IQVIA Holdings Inc. reported revenue of $16.31B. That is +5.87% against the prior fiscal year, when revenue was $15.41B. The same year closed with net income of $1.36B. That is −0.95% against the prior fiscal year. Profit margin runs at 8.1%. That is 8.1 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 7.93.

Across the 4 fiscal years on file, revenue moves from $14.41B in 2022 to $16.31B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

IQV trades at a trailing price-to-earnings ratio of 33.77. That is 2.09% above the Diagnostics & Research median of 33.08. The forward P/E on file is 18.52. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.94. The price-to-sales ratio is 2.6. On price-to-sales that is 47.99% below the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +45.46%. Across 10 years the annualized return works out at +13.28%. The reported beta is 1.19. Daily returns over the trailing 10 years annualize to a volatility of 32.32%.

Growth & Income

The record shows no dividend for IQV.

So far in 2026 the price is +18.79%. The strongest complete calendar year on file is 2021 at +57.47%; the weakest is 2022 at −27.38%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

IQVIA Holdings Inc. (IQV) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IQVIA Holdings Inc. IQV $44.07B 33.8
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. IQVIA Holdings Inc. trades at a P/E of 33.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B

 WAT

Waters Corporation

$40.20B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About IQVIA Holdings Inc.

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Visit website →